A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284
Recruiting · NCT06884098 · Interventional (participants receive a specific treatment) · Lead sponsor: Addpharma Inc.
View the official record on ClinicalTrials.gov →Interventions studied
AD-2284AD-228B
What this trial is about
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.
Who can take part
Age range
19 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
- The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
Exclusion criteria
- Participation in other clinical study with an investigational drug within the 6 months from scheduled first administration
- Other exclusions applied
Where it is running
1 location listed.
- H Plus Yangji Hospital - Seoul, South Korea